Spears Abacus Advisors LLC increased its stake in Celgene Corporation (NASDAQ:CELG) by 0.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 206,430 shares of the biopharmaceutical company’s stock after buying an additional 474 shares during the period. Celgene Corporation accounts for about 3.2% of Spears Abacus Advisors LLC’s holdings, making the stock its 14th largest position. Spears Abacus Advisors LLC’s holdings in Celgene Corporation were worth $25,686,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Stifel Financial Corp increased its stake in shares of Celgene Corporation by 2.8% in the first quarter. Stifel Financial Corp now owns 1,215,960 shares of the biopharmaceutical company’s stock valued at $151,182,000 after buying an additional 32,748 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Celgene Corporation by 10.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 58,050 shares of the biopharmaceutical company’s stock valued at $7,223,000 after buying an additional 5,272 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Prudential Financial Inc. now owns 2,763,704 shares of the biopharmaceutical company’s stock valued at $343,887,000 after buying an additional 24,250 shares during the last quarter. KBC Group NV increased its stake in shares of Celgene Corporation by 13.1% in the first quarter. KBC Group NV now owns 627,150 shares of the biopharmaceutical company’s stock valued at $78,036,000 after buying an additional 72,409 shares during the last quarter. Finally, YHB Investment Advisors Inc. increased its stake in shares of Celgene Corporation by 3.1% in the first quarter. YHB Investment Advisors Inc. now owns 73,675 shares of the biopharmaceutical company’s stock valued at $9,139,000 after buying an additional 2,237 shares during the last quarter. Institutional investors and hedge funds own 79.43% of the company’s stock.

Shares of Celgene Corporation (CELG) traded down 0.16% during midday trading on Tuesday, hitting $131.44. 376,649 shares of the stock traded hands. The company has a market capitalization of $102.83 billion, a P/E ratio of 40.71 and a beta of 1.89. The stock has a 50 day moving average of $133.39 and a 200 day moving average of $125.39. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period in the previous year, the company posted $1.44 EPS. The firm’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities research analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Shares Bought by Spears Abacus Advisors LLC” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.watchlistnews.com/celgene-corporation-celg-shares-bought-by-spears-abacus-advisors-llc/1529719.html.

Several brokerages have recently issued reports on CELG. Vetr downgraded shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a research note on Tuesday. Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a research note on Monday. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research note on Wednesday, August 9th. Cann restated a “buy” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC restated a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a research note on Monday, July 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $147.38.

In related news, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the sale, the insider now owns 1,033,909 shares in the company, valued at $138,688,553.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 253,761 shares of company stock worth $33,792,445. 0.95% of the stock is currently owned by corporate insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.